Evidence
The evidence behind Cytogent.
These are the published numbers behind the problem Cytogent was built to solve. Every number links to its source. We do not publish Cytogent performance numbers until we can support them.
The problem in numbers
What the published evidence says.
Nearly 80% of clinical trials miss initial enrolment targets on schedule; about 19% end early for lack of patients.
Source: Emerald Clinical
Single-country oncology trials take about 36 months to complete enrolment.
A day of Phase III trial conduct costs about $55,716.
Source: Tufts CSDD via DataAlly
About 7.1% of adult cancer patients take part in treatment trials.
23% of physicians account for 84% of trial enrolments in advanced cancer.
Source: JAMA Network Open, 2026
Nearly 3 in 4 oncologists feel overwhelmed by the pace of new treatments.
Source: J&J Oncology Care Index
Oncology assets in development grew about 13% a year (2018 to 2022).
Source: Clinical Trials Arena
Guideline-grounded AI agrees closely with tumour-board decisions and gives safer recommendations than ungrounded models.
Source: Current Oncology, 2026
The problem is not a lack of science. It is a lack of connection. That is what Cytogent builds.
Questions
Quick answers.
Where do these numbers come from?
Every number links to its published source, from peer-reviewed journals to industry analyses.
Are these Cytogent results?
No. They describe the field. We do not publish Cytogent performance numbers until we can support them.
Why do so many trials miss enrolment targets?
Willing patients and open studies often never meet, and the reasons are as much about connection as about science. That gap is what Cytogent addresses.

